72 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B Downtrend
Article Searches
Lilly's Cyramza Successful in Phase III First-Line NSCLC Study http://www.zacks.com/stock/news/359294/lillys-cyramza-successful-in-phase-iii-first-line-nsclc-study?cid=CS-ZC-FT-359294 Mar 13, 2019 - Lilly's (LLY) cancer drug, Cyramza, in combination with erlotinib significantly delays disease progression in a phase III study on previously untreated patients with EGFR-mutated metastatic NSCLC.
Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others http://www.zacks.com/stock/news/359854/pharma-stock-roundup-regulatory-updates-from-mrk-pfe-jj-agn-others?cid=CS-ZC-FT-359854 Mar 15, 2019 - Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.
Merck's Keytruda Gets EU Approval for Difficult Lung Cancer http://www.zacks.com/stock/news/359869/mercks-keytruda-gets-eu-approval-for-difficult-lung-cancer?cid=CS-ZC-FT-359869 Mar 15, 2019 - Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer population in Europe.
AstraZeneca Up This Year on New Drugs & Pipeline Progress http://www.zacks.com/stock/news/359997/astrazeneca-up-this-year-on-new-drugs-pipeline-progress?cid=CS-ZC-FT-359997 Mar 18, 2019 - AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
Top Research Reports for Merck, Adobe & Broadcom http://www.zacks.com/research-daily/360711/top-research-reports-for-merck-adobe-broadcom?cid=CS-ZC-FT-360711 Mar 18, 2019 - Top Research Reports for Merck, Adobe & Broadcom
Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer http://www.zacks.com/stock/news/361461/roches-tecentriq-gets-fda-approval-for-difficult-lung-cancer?cid=CS-ZC-FT-361461 Mar 19, 2019 - Roche (RHHBY) gets an FDA approval of sBLA for Tecentriq in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).
3 Large-Cap Stocks Hitting 52-Week Highs: Are They Buys? https://www.fool.com/investing/2019/03/26/3-large-cap-stocks-hitting-52-week-highs-are-they.aspx?source=iedfolrf0000001 Mar 26, 2019 - Can these big high-flying stocks keep the momentum going?
Why Merck (MRK) is a Top Dividend Stock for Your Portfolio http://www.zacks.com/stock/news/366656/why-merck-mrk-is-a-top-dividend-stock-for-your-portfolio?cid=CS-ZC-FT-366656 Mar 29, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Advaxis Up on Positive Early-Stage Immunotherapy Study Data http://www.zacks.com/stock/news/369278/advaxis-up-on-positive-early-stage-immunotherapy-study-data?cid=CS-ZC-FT-369278 Apr 02, 2019 - Advaxis' (ADXS) immunotherapy candidate, ADXS-PSA, achieves favorable overall survival in mCRPC patients in combination with Merck's Keytruda.
Merck's Keytruda Gets Nod for First-Line Lung Cancer in China http://www.zacks.com/stock/news/369336/mercks-keytruda-gets-nod-for-first-line-lung-cancer-in-china?cid=CS-ZC-FT-369336 Apr 02, 2019 - Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting in China.

Pages: 12345678

<Page 2>